Home

Tobin Schilke

CIK 1678984 · Chief Financial & Infra. Ofcr. · last filed 2026-09-01

Tobin Schilke is a Chief Financial & Infra. Ofcr. who has filed 63 SEC Form 4 insider transactions across 3 companies since 2016. The most recent filing shows the insider disposed of $6.8M of CRNX on Sep 1, 2026. Across all open-market trades the lifetime net is −$2.4M, making them a net seller over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

3

Total Filings

63

Lifetime Open-Market Net

-$2.43M

Filer Profile

Reported Address
CRINETICS PHARMACEUTICALS, INC.
6055 LUSK BOULEVARD
SAN DIEGO, CA 92121
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
CRNX Chief Financial & Infra. Ofcr. 0 $84.95 $0 -$266.3K 5 2026-09-01
Revance Therapeutics, Inc. (RVNC) Delisted CFO 0 $3.65 $0 -$2.07M 43 2025-02-06
Achaogen, Inc. (AKAO) Delisted Chief Financial Officer 48,046 — — -$100.1K 8 2018-06-28

Recent Filings

63 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-09-01 CRNX Disp (D) −79,427 -$6.75M EDGAR
2026-08-24 CRNX Grant (A) +471 $0 EDGAR
2026-03-04 CRNX Sell (S) −6,713 -$266.3K EDGAR
2026-03-02 CRNX Notice (144) −6,800 -$280.0K EDGAR
2026-02-25 CRNX Grant (A) +32,000 $0 EDGAR
2025-03-11 CRNX Grant (A) +52,000 $0 EDGAR
2025-02-06 Revance Therapeutics, Inc. (RVNC) Delisted Mixed −201,554 -$357.7K EDGAR
2025-02-05 Revance Therapeutics, Inc. (RVNC) Delisted Grant (A) +6,888 $0 EDGAR
2025-01-03 Revance Therapeutics, Inc. (RVNC) Delisted Grant (A) +1,000 $2.2K EDGAR
2024-07-02 Revance Therapeutics, Inc. (RVNC) Delisted Grant (A) +1,000 $2.2K EDGAR
Showing 1–10 of 63
Page 1 of 7
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.